[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"endovascular-procedure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:endovascular-procedure":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100656009","phase-3-ticagrelor-versus-placebo-to-prevent-cerebral-ischemia-in-aneurysmal-low-grade-sah-a-double-blinded-randomised-controlled-study-100656009",false,"NCT07821008","TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study","TALISCHER-SAH","Inclusion Criteria:\n\n* Age 18 - 80 years old\n* Low grade aneurysmal subarachnoid hemorrhage defined by a WFNS 1-3\n* Aneurysmal treatment planned to be completed within 72 h after rupture\n* Sacciform aneurysm diameter ≥ 4 mm\n* Ruptured aneurysm treatable by endovascular, endo-saccular technic (stent and flow diverters are not allowed). If the aneurysm responsible of the SAH is difficult to identify, several aneurysms that may be related to the SAH can be treated during the procedure.\n* Affiliated person or beneficiary of a social security scheme.\n* Free, informed and written consent signed by the participant or truthworthy\u002Fproxy representative and the investigator (at the latest on the day of inclusion and before any examination required by the research).\n\nExclusion Criteria:\n\n* Poor grade aSAH defined as WFNS 4 and 5\n* Fusiform, dissecting, thrombosed aneurysms and aneurysm associated with brain arteriovenous malformation\n* Associated unruptured aneurysm requiring treatment within 3 months\n* History of intracranial hemorrhage within the past 6 months\n* Intraparenchymal hematoma associated with SAH -Ongoing antiplatelet drug\n* Acute symptomatic hydrocephalus or ventricular derivation\n* Intra-ventricular hemorrhage on admission CT scan, filling \\>50% of both lateral ventricles and 3rd and 4th ventricles\n* Pre aSAH mRS ≥\n* Active pathological bleeding and notably recent extra cranial hemorrhage (within previous 30 days), gastrointestinal hemorrhage within the past 6 months, or major surgery within 30 days\n* Other contra-indications to Ticagrelor: hypersensitivity to the active substance or to any of the excipients,\n* Severe hepatic or kidney failure,\n* Concomitant administration of strong CYP3A4 inhibitors(for ex ketoconazole, clarithromycine, nefazodone, ritonavir and atazanavir) drugs that interfered with P-glycoprotein transporter\n* Respiratory failure, asthma , obstructive broncho-pneumopathy\n* Pregnant and breastfeeding women\n* Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision","ALL","18 Years","80 Years",{"count":20,"type":21},274,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications. However, preventive strategies are limited. Platelet activation mechanisms play a critical role in the pathophysiology of TEE and DCI. The results of several meta analyses suggested that use of antiplatelet drugs (APD) could reduce the risk of TTE\u002FDCI. We aim to evaluate in patients with a low grade aSAH (WFNS 1 to 3) that occurred for less than 72 hours ago, the effect of 14 days course of ticagrelor vs placebo, initiated at the beginning of the endovascular treatment of the aneurysm, on the ischemic complications (peri-procedural symptomatic and asymptomatic TEE and\u002For neurological worsening due to DCI) occurring within 14 days of the endovascular treatment of the aneurysm.",[27,28,29],"Subarachnoid Hemorrhage, Aneurysmal","Brain Ischemia","Endovascular Procedure",[31,32,33,34,35],"Aneurysmal subarachnoid hemorrhage","platelet aggregation inhibitors","ticagrelor","thromboembolic events","delayed cerebral ischemia","NOT_YET_RECRUITING","2026-09-10",{"date":39,"type":40},"2026-09-15","ACTUAL",{"date":42,"type":21},"2026-09-14",{"date":44,"type":21},"2029-12-14",{"name":46,"class":47},"University Hospital, Toulouse","OTHER",7,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100568337","medico-economic-evaluation-of-the-creation-of-arteriovenous-access-for-hemodialysis-between-surgical-technique-and-endovascular-technique-in-patients-with-end-stage-renal-disease-100568337","NCT06679907","Medico-economic Evaluation of the Creation of Arteriovenous Access for Hemodialysis Between Surgical Technique and Endovascular Technique in Patients with End-stage Renal Disease","Cost-effectiveness Study Comparing Endovascular and Surgical Arteriovenous Fistula Creation for Haemodialysis in Patients with End-stage Renal Failure","ENDOFAV","Inclusion Criteria:\n\nPatients:\n\n* Age\\> 18 years\n* On chronic dialysis, or due to start chronic dialysis within 3 to 6 months\n* Patient eligible for the creation of a native surgical AVF at the elbow crease and an endovenous AVF according to the instructions for use of the manufacturers of the two devices used, namely:\n* Target venous diameter for fistula creation \\> or = 3 mm\n* Target arterial diameter for fistula creation \\> or = 2 mm\n* Artery to vein distance \\\u003C or = 1.5mm\n* At least one superficial outflow vein with a diameter ≥ 2.5 mm connected via a proximal forearm perforating vein with the target site\n* Patency of the radial and ulnar arteries confirmed by Doppler ultrasound\n* Presence of a connecting perforator between the deep and superficial venous network, relatively straight anatomy\n* Distance between proximal radial artery and perforator junction\u002Fradial vein \\\u003C 1.5mm\n* Patient having been clearly informed about the study and having agreed to participate and attend follow-up visits\n* Patient affiliated or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\n* Known central venous stenosis \\> 50% on imaging or presence of an indwelling central venous catheter or pacemaker on the same side as the side of creation of the AVF\n* Upper extremity arterial occlusive disease not amenable to endovascular or open repair\n* Eligibility for a native distal AVF (radio or ulno-cephalic)\n* New York Heart Association (NYHA) class III or IV heart failure\n* Hypercoagulable state\n* Estimated life expectancy \\\u003C1 year\n* Pregnantly or breastfeeding woman\n* Known allergies to medical devices and medications used in the protocol\n* Inability to collect consent\n* Patient not affiliated to a social security scheme",{"count":58,"type":21},252,[60],"NA","This multicenter 1 :1 randomized controlled trial aims at comparing the cost-effectiveness of endovascular arteriovenous fistula (AVF) creation using Ellipsys® and WaveLinQ® devices with traditional surgical AVF creation for hemodialysis. The primary endpoint is the cost-utility ratio (cost per QALY gained), with an anticipated sample size of 252 patients. This study will provide critical insights into the viability and cost-effectiveness of endovascular techniques, potentially shaping future standards of care in hemodialysis access.",[29,63],"Hemodialysis",[63,65,66,67,68,69],"arteriovenous","endovascular","restenosis","cost-effectiveness","health economic evaluation","2024-11-12",{"date":72,"type":40},"2024-11-14",{"date":74,"type":21},"2025-01-15",{"date":76,"type":21},"2030-01-15",{"name":78,"class":47},"University Hospital, Bordeaux",11]